Swisspreneur Show

The $100M TechBio Built Without VCs: Cutiss Co-founder & CEO Daniela Marino (EP #551)

Mar 26, 2026
Daniela Marino, co-founder and CEO of Cutiss and biotech founder who turned academic research into personalized skin therapies. She discusses the NovoSkin personalized skin graft, moving from academia to startup life, building in-house GMP production, navigating phase 3 trials and European regulatory pathways, and raising over CHF 100M without traditional venture capital.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
ADVICE

Build GMP Capacity To Keep Control

  • Avoid outsourcing early GMP manufacturing if losing control risks delays; Daniela built an in-house GMP facility in Schlieren to keep process control.
  • She accepted CapEx objections because owning production accelerated development and reduced dependency on CDMOs.
INSIGHT

NovoSkin Replaces Scar With Regenerative Tissue

  • NovoSkin is an autologous bilayer skin tissue grown from a tiny punch biopsy that permanently integrates and expands with patient growth.
  • It yields better scar quality, elasticity and pliability versus cell sprays or sheets because it provides true regenerative tissue.
ANECDOTE

Clinical Journey From Phase I To Ongoing Phase III

  • Cutiss completed phase I in academia, showed efficacy in phase II with three-year follow-up, and is mid-phase III with 20 European centers open.
  • The next milestone is finishing recruitment, confirming phase II data, then initiating market authorization dialogues.
Get the Snipd Podcast app to discover more snips from this episode
Get the app